Bangladés - inglés - DGDA (Directorate General of Drug Administration)

healthcare pharmaceuticals ltd. - empagliflozin - tablet - 25 mg

Bangladés - inglés - DGDA (Directorate General of Drug Administration)

unimed unihealth pharmaceuticals ltd. - empagliflozin - tablet - 25 mg

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

boehringer ingelheim, germany - empagliflozin - tablet, film coated - 25 mg

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

boehringer ingelheim, germany - empagliflozin - film-coated tablet - 25 mg

Estados Unidos - inglés - NLM (National Library of Medicine)

remedyrepack inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2) - glyxambi is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies (14.2)] . however, the effectiveness of glyxambi on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established. limitations of use glyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis [see warnings and precautions (5.4)] . glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi

Jordania - inglés - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة نهر الاردن للصناعات الدوائية - jordan river pharmaceutical industries - linagliptin 5 mg/1 tab , empagliflozin 25 mg/1 tab - 5 mg/1 tab , 25 mg/1 tab

Jordania - inglés - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة دار الدواء للتنمية والأستثمار - dar al dawa development and investment co ltd - linagliptin 5 mg/1 tab , empagliflozin 25 mg/1 tab - 5 mg/1 tab , 25 mg/1 tab

Namibia - inglés - Namibia Medicines Regulatory Council

ingelheim pharmaceuticals (pty) ltd - empagliflozin - film-coated tablets - each film-coated tablet contains empagliflozin 25 mg

Estados Unidos - inglés - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u) - jardiance is indicated:                  - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, - to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. limitations of use jardiance is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. - history of serious hypersensitivity reaction to empagliflozin or any of the excipients in jardiance [see warnings and precautions (5.7)] . - severe renal impairment, end-stage renal disease, or dialysis [see use in specific populations (8.6)] . risk summary based on animal data showing adverse renal effects, jardiance is not recommended during the second and third trimesters of pregnancy. limited data available with jardiance in pregnant women are not sufficient to determine a drug-associated risk for major birth defects and miscarriage.  there are risks to the mother and fetus associated with poorl

Estados Unidos - inglés - NLM (National Library of Medicine)

remedyrepack inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u) - jardiance is indicated: - to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. - to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use jardiance is not recommended in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . jardiance is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m 2 . jardiance is likely to be ineffective in this setting based upon its mechanism of action. - hypersensitivity to empagliflozin or any of the excipients in jardiance, reactions such as angioedema have occurred [see